Objective: To investigate the therapeutic effects of commonly used selective α-adrenergic receptor antagonists (α-ARA) on benign prostatic hyperplasia (BPH).
Methods: PubMed, Embase and CNKI databases were searched for the literature about selective α-ARAs for the treatment of BPH and the information was extracted on the common adverse reactions in the course of treatment. Multivariate meta-analysis was conducted to investigate the therapeutic effects of different α-ARAs.
Results: The total rates of adverse effects of silodosin and tamsulosin were the highest, 51.9% and 34.0% respectively, with the highest incidences of headache (38.3%), weakness (23.6%) and dizziness (17.5%). Besides, tamsulosin ranked the first in inducing sexual dysfunction of the male patients with BPH (70.4%).
Conclusions: Doxazosin is preferable as the first-choice treatment of BPH for its therapeutic effect and improvement of the patient's quality of life. Silodosin and tamsulosin, however, can be selectively used according to the patient's specific tolerance to different adverse effects.
目的： 探究常用选择性α肾上腺素能受体拮抗剂治疗良性前列腺增生（BPH）的药物疗效。方法： 通过检索PubMed、Embase和CNKI数据库，筛选选择性α肾上腺素能受体拮抗剂治疗BPH的国内外相关文献，提取有关治疗过程中患者发生各种常见不良反应的信息，通过多变量meta分析探索不同α肾上腺素能受体拮抗剂的治疗效果。结果： 共检索237篇相关文献，最终纳入研究13篇。特拉唑嗪和坦索洛新的总不良反应发生率最高，分别是51.9%和34.0%，其中以头痛、虚弱无力和眩晕为发生率最高的不良反应，平均发生率分别约为38.3%、23.6%和17.5%。此外，坦索洛新对BPH患者的性功能方面的影响也居于首位（70.4%）。结论： 多沙唑嗪可以作为BPH患者的首选治疗药物，提高治疗效果及生活质量，而特拉唑嗪和坦索洛新需要根据患者对不同不良反应的耐受性选择性应用。.
Keywords: adverse event; alpha adrenergic receptor antagonist; network meta-analysis; benign prostatic hyperplasia.